A Drug-drug Interaction Study Evaluating the Perpetrator Potential of LY4100511 (DC-853) on Midazolam, Repaglinide, Digoxin, Rosuvastatin in Healthy Participants
Completed · Phase 1 · NCT06503679
Conditions: Healthy
At a glance
- Research payments reported, 2025
- $1.3M
- U.S. investigators named
- 1
- Sites paid
- 2
- Planned or actual enrollment
- 49
About the trial
- Sponsor
- DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
- Tested
- LY4100511 (DC-853) Dose 1 (drug), LY4100511 (DC-853) Dose 2 (drug), LY4100511 (DC-853) Dose 3 (drug), Midazolam (drug), Repaglinide (drug), Digoxin (drug), Rosuvastatin (drug)
- Dates
- Started 2024-07-16; completion 2024-12-31
- Results posted
- Not yet
The main purpose of this study is to assess the safety and tolerability and pharmacokinetics of LY4100511 (DC-853) when administered alone or in the presence of cytochrome P450 substrates in healthy participants.
From ClinicalTrials.gov, last updated 2025-01-24. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $1.3M in research payments for this study in 2025 (2 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Covance Clinical Research Unit Inc $753,396
- Covance Clinical Research LP Dallas $596,411
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.